List view / Grid view
7 December 2015 | By Victoria White
Betalutin is the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL)...
6 December 2015 | By ProteinSimple
This video provides an overview of the features from the Simple Western product range by ProteinSimple, including Wes, Sally Sue, Peggy Sue or NanoPro 1000...
5 December 2015 | By ProteinSimple
Ella runs hands-free, multiplex-free, ELISA-free Simple Plex assays. She’ll give you results for multiple samples in 60 minutes flat...
4 December 2015 | By ProteinSimple
Address the US FDA requirement to characterize and quantify protein aggregates and other particle contaminants sized 1-70 microns in biotherapeutics...
3 December 2015 | By Victoria White
Researchers say nanobombs might overcome a biological barrier that has blocked development of agents that work by altering the expression of genes in cancer cells...
3 December 2015 | By Drug Target Review
Included in this issue: Biomarkers, Mass Spectrometry, Target Validation, Drug Development, Personalised Medicines, Next-Generation Sequencing, Protein Expression, Companion Diagnostics, and much more...
In this Mass Spectrometry In-Depth Focus: Michelle M. Hill from University of Queensland discusses Mass spectrometric and systems biology approaches in drug target discovery, and Nicola Burgess-Brown, Rod Chalk, Claire Strain-Damerell and Pravin Mahajan from the Structural Genomics Consortium look at analysing recombinant proteins by mass spectrometry...
Knowledge about cancer biomarkers has increased tremendously and provides clinicians and researchers with valued opportunities to understand the molecular mechanism of cancer, thus applying it to effective, early-stage diagnosis and treatment. Cancer biomarkers include a vast range of biochemical molecules such as nucleic acids, proteins, sugars, lipids, small metabolites, cytogenetic…
The pharmaceutical industry is searching for novel drug targets that could produce the next generation of ‘first-in-class’ therapeutic agents. The challenge for academia is to identify and translate such targets and to provide starting points and confidence in the underlying science. The aim should be to generate evidence that modulation…
Progress in the understanding of disease mechanisms provides new opportunities to discover molecules that modulate disease. To capitalise on these opportunities, successful lead discovery strategies need to build on insights into how a cellular phenotype or a target contributes to disease biology. Recent advances in induced pluripotent stem cells (iPSCs),…
2 December 2015 | By Victoria White
GBI Research states that the majority of oncology therapeutics are in the early stages of the pipeline, with 2,937 at the Preclinical stage and 1,591 at the discovery stage...
2 December 2015 | By Victoria White
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Centre are to focus on developing new medicines for pancreatic ductal adenocarcinoma...
2 December 2015 | By ProteinSimple
Simple Western™ system for the characterization of post-translational protein modification by the detection of charge isoforms...
1 December 2015 | By Victoria White
Amcure will use the €1.9 million grant to support the initiation of first-in-man studies for the company's lead candidate for the treatment of epithelial tumours...
30 November 2015 | By Victoria White
Heptares and Pfizer have announced they are to research and develop potential new medicines directed at up to 10 G protein-coupled receptor (GPCR) targets across multiple therapeutic areas...
